Abstract:Background Myelofibrosis is the most aggressive subtype among classical BCR::ABL1 negative myeloproliferative neoplasms. About 90% of cases are driven by constitutive activation of 1 of 3 genes impacting the JAK/STAT pathway: JAK2, CALR , and MPL . Triple-negative myelofibrosis (TN-MF) accounts for only 5-10% of cases and carries the worst outcomes. Little has been described about this subset of disease. Given the marked heterogeneity surrounding disease biology, clonal architecture, clinical presentation, and poor outcomes in TN-MF, identification of features of interest and assessment of treatment response are areas in need of further investigation. Patients and methods We collected and evaluated baseline clinical and molecular parameters from 626 patients with a diagnosis of myelofibrosis who presented to the H. Lee Moffitt Cancer Center in Tampa (Florida, US) between 2003-2021 and compared them based on presence or absence of the three classical phenotypic driver mutations. Results A small proportion of patients (6%) harbored TN-MF which correlated with inferior outcomes, marked by a 4-year reduction in overall survival time compared to the non-TN cohort (mOS 37.4 months vs. 85.7 months; p=.009) and higher rates of leukemic transformation. More pronounced thrombocytopenia and anemia, lower LDH, EPO levels, as well as lower percentage of marrow blasts at baseline were more commonly seen in TN-MF (p<0.05). Similarly, patients with TN-MF had higher risk disease per DIPSS+ and GIPSS. Mutations impacting RNA splicing, epigenetic modification and signaling, specifically SRSF2, SETBP1, IDH2, CBL and GNAS , were more commonly seen among those lacking a classical phenotypic driver. The prevalence of co-mutant ASXL1 / SRSF2 clones was significantly higher in TN-MF as was trisomy 8. TN patients had fewer responses (46.2% vs 63.4%) and shorter duration of response to ruxolitinib. Conclusion TN-MF is invariably associated with significantly decreased survival and more aggressive clinical behavior with higher rates of leukemic transformation and shorter duration of response to ruxolitinib. Mutations impacting RNA splicing, epigenetic modification and signaling ( SRSF2, SETBP1, IDH2, CBL and GNAS) are more common in TN-MF, which likely drive its aggressive course and may account for suboptimal responses to JAK inhibition. Micro Triple-negative myelofibrosis (MF) constitutes a distinct disease subset marked by aggressive clinical features, higher rates of leukemic transformation, shorter duration of response to ruxolitinib and poor survival. Mutations affecting epigenetic modification, RNA splicing and signaling likely drive its hostile course and may account for suboptimal responses to JAK inhibition.

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients

Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?

CALR mutation burden in essential thrombocythemia and disease outcome

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

Clinical Relevance Between CALR Mutation and Myeloproliferative Neoplasms.

Prognostic Value of CALR Vs. JAK2V617F Mutations on Splenomegaly, Leukemic Transformation, Thrombosis, and Overall Survival in Patients with Primary Fibrosis: a Meta-Analysis

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review

Elevated Expression of the EZH2 Gene in CALR -Mutated Patients with Primary Myelofibrosis

Progress of CALR Gene Mutation in Myeloproliferative Neoplasm

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis

Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations

A New Molecular Marker for Myeloproliferative Neoplasms:Calr Mutations

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes

Clinical Implications of Cancer Gene Mutations in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide.

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial